Results 101 to 110 of about 17,288,534 (269)

Bio-Medical Library Bulletin, No. 89 (1986-02)

open access: yes, 1986
Bio-Medical Library. (1986). Bio-Medical Library Bulletin, No. 89 (1986-02).
Bio-Medical Library
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Bio-Medical Library Bulletin, No. 07 (1969-05)

open access: yes, 1969
Bio-Medical Library. (1969). Bio-Medical Library Bulletin, No. 07 (1969-05).
Bio-Medical Library
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Bio-Medical Library Bulletin, No. 28 (1972-12)

open access: yes, 1972
Bio-Medical Library. (1972). Bio-Medical Library Bulletin, No. 28 (1972-12).
Bio-Medical Library
core  

The Bio-Economy Concept and Knowledge Base in a Public Goods and Farmer Perspective

open access: yes, 2012
Currently an industrial perspective dominates the EU policy framework for a European bio-economy. The Commission’s proposal on the bio-economy emphasises greater resource-efficiency, largely within an industrial perspective on global economic ...
Padel, Susanne   +7 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Bio-Medical Library Bulletin, No. 77 (1983-02)

open access: yes, 1983
Bio-Medical Library. (1983). Bio-Medical Library Bulletin, No. 77 (1983-02).
Bio-Medical Library
core  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Bio-Medical Library Bulletin, No. 53 (1977-09)

open access: yes, 1977
Bio-Medical Library. (1977). Bio-Medical Library Bulletin, No. 53 (1977-09).
Bio-Medical Library
core  

Home - About - Disclaimer - Privacy